Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster discussion - Basic science

2713 - Joined analysis of Sarcomatoid Carcinoma (SC) mutational profiles: comparison of lung versus head and neck cancer.


22 Oct 2018


Poster discussion - Basic science


Translational Research

Tumour Site

Head and Neck Cancers


Nicolas Pecuchet


Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304


N. Pecuchet1, R. Taouachi2, A. Ben Lakhdar3, V. Fallet4, N. Rabbe5, H. Blons6, A. Lemoine7, M. Antoine8, S. Temam9, P. Laurent-Puig10, M. Wislez11

Author affiliations

  • 1 Umrs-1147, Paris Descartes University, 75006 - Paris/FR
  • 2 Head And Neck Cancer Department, Gustave Roussy InstituteGustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 3 Pathology, Gustave Roussy InstituteGustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 4 Thoracic Oncology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 5 Grc N°04, Theranoscan, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 6 Biochimie Uf De Pharmacogénétique Et Oncologie Moléculaire, Hopital European George Pompidou, 75015 - Paris/FR
  • 7 Biochemistry, Hopital Paul Brousse - Paris Sud Hospital, 94804 - Villejuif/FR
  • 8 Department Of Cytology And Pathology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 9 Head And Neck Cancer Department, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 10 Umrs-1147 - Department Of Biochemistry, Pharmacogenetic And Molecular Oncology Unit, Paris Descartes University - Georges Pompidou European Hospital, 75006 - Paris/FR
  • 11 Pneumology, Grc N°04, Theranoscan, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2713


SC is a rare tumor of lung and head and neck. In a previous study, lung SC (LSC) have been classified in 2 molecular clusters (C) based on mutational signatures and oncogenic drivers: C1 marked by tobacco-associated signature 4 and C2 marked by homologous repair deficiency signature 3 and APOBEC-associated signatures 2 and 13. We aimed to assign this classification to head and neck SC (HNSC).


Whole exome sequencing was performed in 15 LSC and 6 HNSC. Mutations have been called using Mutect2 (GATK v4.0). In addition, 10 LSC published by Liu et al. were included. Mutational signatures described by Alexandrov et al. have been called using DeconstructSigs. Oncogenic mutations were reported in known cancer-associated genes. Unsupervised clustering based on mutational signatures was performed using NMF.


Clinical characteristics of LSC were male (10/15), smokers (15/15), aged <60yrs (4/10) and pleomorphic carcinomas (n = 14/15). HNSC were male (6/6), smokers (6/6), aged <60yrs (4/6) and pleomorphic carcinomas (n = 5/6). Heavy alcohol consumption was reported for HNSC (3/6). Samples clustering based on mutational signatures confirmed the 2 previously described clusters plus one additional cluster: C1 (n = 13) associated with Signatures 4 and 8; C2 (n = 18) associated with Signatures 1, 2, 3 and 13; C3 associated with Signature 16 (unknown factor). Thirteen, 9 and 3 LSC versus 0, 2 and 4 HNSC were classified in C1, C2 and C3, respectively (p-value < 0.01). The 3 patients with high alcohol consumption HNSC were C3. C1 LSC had KRAS (n = 8), NRAS (n = 1), RRAS (n = 1) mutations. C2 LSC had MET (n = 2), KRAS (n = 2), BRCA2 (n = 2), BRCA1 (n = 1), EGFR (n = 1) and IDH1 (n = 1) mutations. C3 LSC had MET (n = 2) and MAP2K1 (n = 1). By contrast, C2 and C3 HNSC had FAT1 (n = 3) and HRAS (n = 1) mutations, which are frequent in head and neck squamous cell carcinomas.


Joined analysis of SC identified a group C3 associated with signature 16, which has been associated with liver cancers and a putatively link with DNA damage of alcohol metabolites. Although sharing similar histology, these results suggest that HNSC differs from LSC regarding mutational processes and oncogenic events: C1 limited to LSC, C2 found in LSC and HNSC and C3 more associated with HNSC.

Clinical trial identification

Legal entity responsible for the study

Marie Wislez.


Legs Poix La Chancellerie des Universités de Paris - La Ligue Contre le Cancer - Comite de Paris.

Editorial Acknowledgement


N. Pecuchet: Employee: Dassault Systemes. H. Blons: Speaker honoraria: AstraZeneca, Boehringer Ingelheim, Pfizer; Travel funding: AstraZeneca. A. Lemoine: Honoraria: AstraZeneca, Boehringer Ingelheim, Roche. M. Wislez: Consulting/advisory role: AstraZeneca, Roche, BMS, MSD, Novartis, Boehringer Ingelheim; Research funding: BMS, Boehringer Ingelheim; Travel, accommodations, expenses: Roche, BMS, Novartis, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.